Next Article in Journal
Molecular Cloning and Characterization of PnbHLH1 Transcription Factor in Panax notoginseng
Next Article in Special Issue
Bioactive Compounds from Mexican Varieties of the Common Bean (Phaseolus vulgaris): Implications for Health
Previous Article in Journal
Development of 2-Methoxyhuprine as Novel Lead for Alzheimer’s Disease Therapy
Previous Article in Special Issue
Resveratrol Improves Glycemic Control in Type 2 Diabetic Obese Mice by Regulating Glucose Transporter Expression in Skeletal Muscle and Liver
Open AccessArticle

Development of a UPLC-MS/MS Method for Simultaneous Determination of Six Flavonoids in Rat Plasma after Administration of Maydis stigma Extract and Its Application to a Comparative Pharmacokinetic Study in Normal and Diabetic Rats

School of Pharmacy, China Medical University, 77 Puhe Road, Shenyang 110122, China
*
Author to whom correspondence should be addressed.
Molecules 2017, 22(8), 1267; https://doi.org/10.3390/molecules22081267
Received: 23 June 2017 / Revised: 12 July 2017 / Accepted: 27 July 2017 / Published: 29 July 2017
Maydis stigma is an important medicine herb used in many parts of the world for treatment of diabetes mellitus, which main bioactive ingredients are flavonoids. This paper describes for the first time a study on the comparative pharmacokinetics of six active flavonoid ingredients of Maydis stigma in normal and diabetic rats orally administrated with the decoction. Therefore, an efficient and sensitive ultra high performance liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS) method for the simultaneous determination of six anti-diabetic ingredients (cynaroside, quercetin, luteolin, isorhamnetin, rutin and formononetin) of Maydis stigma in rat plasma has been developed and validated in plasma samples, which showed good linearity over a wide concentration range (r2 > 0.99), and gave a lower limit of quantification of 1.0 ng·mL−1 for the analytes. The intra- and interday assay variability was less than 15% for all analytes. The mean extraction recoveries and matrix effect of analytes and IS from rats plasma were all more than 85.0%. The stability results showed the measured concentration for six analytes at three QC levels deviated within 15.0%. The results indicated that significant differences in the pharmacokinetic parameters of the analytes were observed between the two groups of animals, whereby the absorptions of these analytes in the diabetic group were all significantly higher than those in the normal group, which provides an experimental basis for the role of Maydis stigma in anti-diabetic treatment. View Full-Text
Keywords: Maydis stigma; anti-diabetic ingredients; UPLC-MS/MS; rat plasma; pharmacokinetics Maydis stigma; anti-diabetic ingredients; UPLC-MS/MS; rat plasma; pharmacokinetics
Show Figures

Graphical abstract

MDPI and ACS Style

Wei, B.-B.; Chen, Z.-X.; Liu, M.-Y.; Wei, M.-J. Development of a UPLC-MS/MS Method for Simultaneous Determination of Six Flavonoids in Rat Plasma after Administration of Maydis stigma Extract and Its Application to a Comparative Pharmacokinetic Study in Normal and Diabetic Rats. Molecules 2017, 22, 1267.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop